RA Capital Exercises 2.1M Pre-Funded Warrants, Board Member Resigns
VOR has more than doubled off its 52-week low of $6.5.
Summary
RA Capital exercised 2.1 million pre-funded warrants, boosting its stake to 19.9% of Vor Biopharma. Board member Andrew Levin also resigned.
Key Events · Ownership and Investor Activity · VOR
-
Warrant Exercise Increases Stake
RA Capital exercised 2,100,000 pre-funded warrants at $0.002 per share on a cashless basis, receiving 2,099,787 shares. This raises its beneficial ownership to 12,937,855 shares, or 19.9% of outstanding common stock.
-
Board Resignation
Andrew Levin resigned from the Board of Directors effective July 6, 2026. The filing does not state a reason.
-
Ownership Structure
RA Capital's stake includes 4,501,882 shares held directly, warrants for 1,056,072 shares, pre-funded warrants for 7,900,000 shares (subject to a 19.99% blocker), and stock options for 6,689 shares.
Analysis · VOR · Life Sciences
RA Capital, a major institutional holder, exercised 2.1 million pre-funded warrants at a nominal price, increasing its stake to 19.9% of outstanding shares. The cashless exercise added 2,099,787 shares without providing new capital to the company. Separately, board member Andrew Levin resigned effective July 6, 2026, which may signal governance shifts. The warrant exercise is a significant ownership event, though as a financial investor, RA Capital's actions are less indicative of operational conviction than insider purchases.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VOR was trading at $20.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.50 to $53.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.